| abstract |
The present invention aims to provide an anti-human Tie2 antibody, which prevents or treats diabetic macular edema, diabetic retinopathy and critical limb ischemia by binding to human Tie2 and activating the human Tie2. The present inventors conducted research on anti-human Tie2 antibody, and thus provided an anti-human Tie2 antibody comprising 4 heavy chain variable regions and 4 light chain variable regions. The heavy chain variable region consists of the amino acid sequence of amino acids 1 to 122 of SEQ ID NO:2, and the light chain variable region consists of the amino acid sequence of amino acids 1 to 113 of SEQ ID NO:4. One of the variable regions of the heavy chain and one of the variable regions of the light chain constitute one antigen-binding site, and the antibody comprises four antigen-binding sites. |